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MINIREVIEWS

Drug delivery interfaces: A way to optimize inhalation
therapy in spontaneously breathing children
Arzu Ari
and often overlook the importance of interface selection
that lead to suboptimal drug delivery and therapeutic
response in neonates and pediatrics. Therefore, it
is necessary to critically assess each interface and
understand its advantage and disadvantages in aerosol
drug delivery to this patient population. The purpose
of this paper is to provide a critical assessment of drug
delivery interfaces used for the treatment of children
with pulmonary diseases by emphasizing advantages
and problems associated with their use during inhalation
therapy.
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Core tip: Many interfaces exist for aerosol drug delivery
to spontaneously breathing children and inhalation
therapy with different interfaces has become an impor
tant topic of interest among clinicians. However, clini
cians usually focus on selecting the right drug-device
combination and often overlook the importance of
interface selection that lead to suboptimal drug delivery
and therapeutic response in neonates and pediatrics.
This paper provides a critical assessment of drug
delivery interfaces used for the treatment of children
with pulmonary diseases by emphasizing advantages
and problems associated with their use during inhalation
therapy.
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Abstract

Ari A. Drug delivery interfaces: A way to optimize inhalation
therapy in spontaneously breathing children. World J Clin
Pediatr 2016; 5(3): 281-287 Available from: URL: http://www.
wjgnet.com/2219-2808/full/v5/i3/281.htm DOI: http://dx.doi.
org/10.5409/wjcp.v5.i3.281

There are several different types of drug delivery
interfaces available on the market. Using the right inter
face for aerosol drug delivery to children is essential for
effective inhalation therapy. However, clinicians usually
focus on selecting the right drug-device combination
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mouthpiece in their mouth with an adequate seal during
inhalation therapy, the mouthpiece is not the right
[16-19]
interface for them
. Therefore, when a mouthpiece
cannot be used by a child, choosing another interface
such as facemask, high flow nasal cannula or hood
is important to improve the efficiency and efficacy of
aerosol drug delivery to neonates and pediatrics.

INTRODUCTION
There are several different types of drug delivery
interfaces available on the market. Using the right
interface for aerosol drug delivery to children is essential
for effective inhalation therapy. However, clinicians
usually focused on selecting the right drug-device
combination and often overlooked the importance
of interface selection that lead to suboptimal drug
delivery and therapeutic response in neonates and
[1-6]
pediatrics . Therefore, it is necessary to critically
assess each interface and understand its advantage
and disadvantages in aerosol drug delivery to neonates
and pediatrics. The purpose of this paper is to provide a
critical assessment of drug delivery interfaces used for
the treatment of children with pulmonary diseases by
emphasizing advantages and problems associated with
their use during inhalation therapy.

FACEMASK
Facemasks are commonly used for aerosol drug delivery
to children until they develop sufficient understanding
to inhale through the mouthpiece during inhalation
therapy. In children who cannot use a mouthpiece until
3 years of age, clinicians should consider using a wellfitting facemask. Therefore, it is essential to select
a lightweight and flexible facemask with anatomic
contours and small dead space in order to increase
tolerability of facemask by children during inhalation
[20,21]
therapy
. Using smaller masks with less dead space
in neonates will lead to a greater inhaled dose especially
with use of aerosol devices such as mesh nebulizers
or pMDIs that do not add gas to the system during
treatment.
Facemasks designs can be divided into two cate
gories: (1) front-loaded facemasks and (2) bottomloaded facemasks. Front-loaded facemasks have
small entrainment ports on the side of the mask and
direct aerosol toward the oronasal area of the patient
as opposed to bottom-loaded masks that direct
aerosol toward the upper part of the mask. Previous
research reported that aerosol deposition with the
front-loaded facemask (Bubbles Fish II Mask, PARI,
Midlothian, Virginia) was greater than bottom-loaded
[8,22-24]
facemask
. They also have lower deposition in the
eye and face compared with bottom-loaded facemask
[22,23,25]
designs
.
When a facemask is used for aerosol drug delivery
to neonates or pediatrics, clinicians should have a good
face-mask seal to maximize the efficiency of treatment
and prevent the drug from getting to the eyes and the
face of children. However, keeping a good face-mask
seal during inhalation therapy is frequently associated
with crying and rejection of the facemask. Previous
research showed that aerosol drug delivery to children
will decrease significantly without an optimum face-mask
seal because of leaks, crying or children intolerance of
[2-4,22,25-29]
[30]
the facemask
. Janssens et al suggested that
administration of inhaled medications while children are
asleep may be a viable option for inhalation therapy
because children have more regular breathing patterns
during sleep that may lead to greater lung deposition
and better patient outcomes. However, Esposito[31]
Festen et al reported that 69% of the young children
woke up and 75% of them distressed during inhalation
therapy with the pMDI and VHC combination.
In the past, clinicians believed that crying improves
aerosol drug delivery to children because of the large
breath at the end of the cry. However, crying results in a

BLOW-BY
Blow-by is a technique that is used with a jet nebulizer
placed within a distance from the child and directs
aerosol plume towards the patient’s face. Historically,
aerosolized medications were delivered to neonates
and pediatrics using blow-by because it was considered
to be an effective technique especially for crying,
fussing and uncooperative children. Also, many parents
preferred to use blow-by, a mask-free aerosol delivery
technique, to avoid struggling with their children during
inhalation therapy.
However, there are several disadvantages of this
technique. For instance, it cannot be used with pres
surized metered-dose inhalers (pMDIs) with valved
holding chambers (VHCs) and breath-actuated nebuli
zers due to poor mask seal that will inhibit valve
[7]
opening . Also, blow-by cannot be used with mesh
[7]
nebulizers due to lack of supplemental gas flow .
Previous research reported that blow-by is not efficient
in aerosol drug delivery to children because it results
[8-11]
in 50%-85% lower dose than the facemask
.
Therefore, using blow-by for aerosol therapy is not
[7,11-13]
recommended
.
Problems associated with blow-by highlight not
only the importance of interface selection in inhalation
therapy, but also finding a better alternative for deli
vering aerosolized medications to neonates and
pediatrics. Mouthpiece, facemask, nasal mask, pasifier
mask, hood, high flow nasal cannula and VHCs may be
viable choices of interface in children and the following
sections will describe each interface more in detail.

MOUTHPIECE
Previous in vitro studies showed that aerosol delivery
via a mouthpiece may provide twice as much drug
compared with a facemask and is the most effective inter
[14,15]
face in spontaneously breathing older pediatrics
.
Since children less than 3 years of age cannot keep the
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Figure 1 Soother mask (Reproduced with permission from the
InspiRx, Somerset, New Jersey).

very long exhalation followed by fast and short inhalation
that leads to deposition of aerosolized medications in
the upper respiratory track than in the lower respiratory
therapy track. Also, it is difficult to have a good seal with
the facemask when a baby cries. Using a facemask with
[32]
the pMDI - VHC, Tal et al
found that lung deposition
of babies crying was 0.35% as opposed to 2% when
[33]
they have quite breating. Similarly, Murakami et al
showed that aerosol deposition in a crying infant using
a facemask with a nebulizer was negligible and Iles
[34]
et al
reported a 4-fold decrease in lung deposition
when infants were crying. According to the findings
[35]
of the study conducted by Wildhaber et al
the
gastrointestinal deposition in crying children was 50%
higher than their non-crying peers.

and pediatrics is superior or more effective than oral
[39,40]
delivery
, aerosol delivery through high flow nasal
cannula (HFNC) has become a popular procedure in
the treatment of children with pulmonary diseases.
Several in vitro studies evaluated aerosol drug delivery
[41-44]
through HFNC in infants and pediatrics
. Using
dose quantification with the laser diffraction technique,
[43]
Bhashyam et al determined the efficiency of inhalation
therapy through adult and pediatric HFNC with a mesh
nebulizer placed downstream of a heated humidifier.
They reported that aerosolized medications could be
efficiently delivered to pediatrics through HFNC. Ari
[44]
et al
compared aerosol drug delivery with heliumoxygen mixture (heliox) and oxygen at 3 L/min and 6
L/min, using a pediatric HFNC with a mesh nebulizer
placed on the inspiratory inlet of a heated humidification
system. They reported that bronchodilator delivery
with heliox at 3 L/min was similar to that with oxygen
whereas heliox delivered 2 fold greater aerosol than
[42]
oxygen at 6 L/min. Sunbul et al
evaluated bron
chodilator delivery using HFNC, bubble continuous
positive airway pressure (CPAP) and sigh intermittent
mandatory ventilation (SiPAP) with a mesh nebulizer
placed proximal to the patient interface and prior to
the humidifier. Using spontaneously breathing lung
model attached to a low-birth-weight anatomic nasal
airway cast, they showed that aerosol delivery with
SiPAP was lower than HFNC and the Bubble CPAP.
Aerosol deposition through HFNC was less than 2%
but higher than drug delivery with the Bubble CPAP.
Also, nebulizer placement at the humidifier resulted in
greater aerosol deposition in HFNC, SiPAP and Bubble
[42]
[41]
CPAP . According to Perry et al HFNC should not be
used for bronchodilator delivery to children because the
amount of aerosol deposition obtained with different
cannula sizes of flows used with HFNC was lower than
the amount needed for a clinical response. Also, skin
irritation and condensate accumulating in the cannula
are potential issues with HFNC. Therefore, clinical
studies evaluating the safety and efficacy of aerosol
drug delivery with HFNC are warranted.

PACIFIER MASK
As a new and innovative development of chidrenoriented drug delivery interface, the pacifier mask
(Soother Mask, InspiRx, Somerset, New Jersey) was
designed to achieve therapeutic lung deposition in
children by eliminating their discomfort, fear and cry
with the conventional facemask and keeping them calm
through a pacifier. It includes the infant’s own pacifier
that is attached to the anterior wall of the mask (Figure
1). The infant keeps the Soother mask sealed to his face
by sucking the pacifier during treatment while nasally
inhaling aerosolized medications generated by pMDIs/
[36,37]
VHCs or nebulizers during inhalation therapy
. Amirav
[38]
et al compared the Soother mask with a conventional
bottom-loaded face mask on bronchodilator delivery in
12 infants less than 1 year of age. Using scintigraphic
measurements of aerosol deposition in infants, they
reported that lung deposition with the Soother Mask
was similar to that with the conventional face mask
[38]
without a pacifier . Since sucking calms children, the
Shooter Mask can be used for prolonged periods of time
without rejection by infants and improves compliance to
[18,36-38]
aerosol treatments in infants
.

HIGH FLOW NASAL CANNULA
Infants and young children are nose breathers.
Since previous research showed that nasal delivery
of aerosolized medications to the lungs of infants
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Table 1 Descriptions, advantages and disadvantages of each interface used for aerosol drug delivery to spontaneously breathing
neonates and pediatrics
Interface

Description

Blow-by

A technique that directs aerosol
plume towards the patient’s face
by placing a jet nebulizer within a
distance from the child that ranges
from 1 to 30 cm

Advantages

Disadvantages

Suggestions for the best practice

Easy to use
Inefficient aerosol drug delivery to Inhalation therapy with blowComfortable and easy to
children
by is not efficient; therefore, it
tolerate by the patient
Drug delivery with blow-by is
should not be used for aerosol
A mask-free aerosol delivery
50%-85% less than the facemask
drug delivery to neonates and
technique
Cannot be used with pMDIs,
pediatrics
Used with fussing, crying and breath- actuated nebulizers and
uncooperative children
mesh nebulizers
Mouthpiece
A cylindrical tube that extends
Efficient inhalation therapy in
Children less than 3 yr of age
The mouthpiece should not be
between the lips so that aerosol can
children
cannot use a mouthpiece
used for children who are less
pass through the oropharynx to reach Aerosol drug delivery with a
An adequate consistent seal is
than 3 yr old
lower respiratory tract
mouthpiece is two-fold more needed during inhalation therapy When using a mouthpiece child
than that with a face mask
should be encouraged to keep it
in their mouth during therapy
If a child cannot keep the
mouthpiece in his mouth with
an adequate seal during aerosol
drug delivery, another interface
should be used for inhalation
therapy
Facemask
An interface that covers the nose and Can be used in children all A good facemask seal is needed for Select a lightweight and flexible
mouth. It is kept in place through an
years of age
optimum aerosol drug delivery
facemask with anatomic
elastic band that extends beyond the Can be used with nebulizers
Is frequently associated with
contours to increase tolerability
back of the head or neck
and pMDIs to deliver
crying, intolerance and rejection of of face mask by children during
aerosolized medications to
the mask
therapy
neonates and pediatrics
Crying and leaks between face
Choose a facemask with small
and mask decrease aerosol drug
dead space and have a good
delivery to children
face-mask seal to increase
delivery efficiency of inhalation
therapy
Use another interface if the
patient starts to fuss, and cry
during aerosol drug delivery
with a facemask
Pacifier mask A face mask with the attachment of
A new and innovative
May be a good option for
the infant’s own pacifier
facemask design that
children who fuss, cry and does
eliminates fear, discomfort
not tolerate other interfaces used
and cry with the standard
for aerosol drug delivery in
facemask
neonates and pediatrics
A children-oriented drug
delivery interface designed
to achieve therapeutic lung
deposition in children
Improves compliance to
inhalation therapy in infants
Nasal mask
An interface that covers the nose
Easy to use
Aerosol delivery with the nasal
to allow aerosol to pass through
Better tolerance than the
mask is less than that with the
the nasopharynx to reach the lower
facemask
standard facemask
respiratory tract
High flow
A tubing with two small prongs that
Efficient delivery of
More information about the
When using mesh nebulizers
nasal
are inserted into the nares to allow
aerosolized medications to
safety and efficacy of aerosol drug
for aerosol drug delivery to
cannula
aerosol pass through the nasopharynx
neonates and pediatrics
delivery though HFNC is needed neonates and pediatrics, place
and reach the lower respiratory tract Children may tolerate HFNC
Cannot be used with pMDIs
the nebulizer prior to the heated
better than the facemask
humidifier
Hood
An enclosure that covers the head
A good option for aerosol
User may need additional training Use the hood for aerosol drug
and neck of a neonate or small
delivery to children who
and practice to provide proper
delivery to children who cannot
children to deliver aerosol to the
cannot use a mouthpiece and inhalation therapy with the hood
use a mouthpiece and tolerate
lungs while isolating it from ambient
tolerate the facemask
More time and parts may be
the facemask
air
Likelihood of agitating infants
needed for the set-up
Put the infant in the face-side
and making them cry is low
position when using the hood
Aerosol delivery with the
for inhalation therapy because it
hood is the same as the
has less facial-ocular deposition
facemask
than face-up position
Parents prefer the hood over
the mask
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Valved
holding
chamber

A chamber shaped interface with a
one-way valve that allows aerosols to
be contained in the chamber during
aerosol therapy

Reduces oropharyngeal
Electrostatic charge and large
Wash the VHC with detergent
deposition
volume VHCs result in a decrease
and air dry before inhalation
Minimize hand-breath
in aerosol drug delivery to children therapy in order to eliminate
coordination during
static charge and improve
inhalation therapy
aerosol delivery to neonates and
Improves efficiency of aerosol
pediatrics
therapy
Choose small volume VHCs for
aerosol therapy
Actuate one-dose at a time into
VHC instead of multiple doses

VHC: Valved holding chambers; pMDIs: Pressurized metered-dose inhalers.

aerosol drug delivery to neonates and pediatrics. The
nasal mask is a special type of mask that is placed over
the nasal airway during inhalation therapy. A recent in
vitro study showed that aerosol delivery with the nasal
mask was less than that with the facemask in simulated
spontaneously breathing infants and young children
[24]
using a jet nebulizer .

Therefore, it is important to use small volume spacers
or VHCs so that the concentration of aerosol in the VHC
is kept higher and children can inhale all the medication
in less time with fewer breaths. Parents need to be
educated to actuate one dose at a time into VHC instead
of multiple doses and let their children inhale from VHC
[12,57]
right after the pMDI has been actuated
.

HOOD

EDUCATING PARENTS ABOUT
INTERFACES USED IN INHALATION
THERAPY

Hood is a good option for aerosol drug delivery to
children who cannot use a mouthpiece and tolerate the
[18,45-48]
facemask
. Since there is no attachment to the
patient’s face, the likelihood of agitating infants and
making them cry with the use of hood for inhalation
therapy may be less than facemasks. Aerosol drug
delivery via hood is easy to operate and often provided
[49]
when infants are asleep. Amirav et al
showed that
bronchodilator delivery with the hood and facemask
was similar (2.6% and 2.4%, respectively) in 14
[47]
wheezing children. Kugelman et al reported that both
treatment time and discomfort were lower in infants
[48]
using the hood. In another study, Amirav et al found
that respiratory scores of infants with bronchiolitis
received aerosol therapy with the hood and facemask
were similar, but parents preferred the hood over the
[48]
masks . It is also important to ensure the optimal
[50]
position of the child within the hood. Kim et al found
similar lung deposition in face-up and face down posi
tions during hood nebulization; however, the face-side
position has less facial-ocular deposition than face-up
position.

Typically, inhaled medications are prescribed without
demonstrating parents how inhalation therapy should be
undertaken with each device and interface. Therefore,
parents don’t know how to use each interface and how
to solve problems that may arise during aerosol drug
delivery to children. For instance, when their baby
fights with the facemask, some parents may decide
to use blow-by without knowing that it will reduce
the efficiency of therapy and others force the baby to
accept the facemask by holding it tightly on the baby’
s face and believing that crying improves aerosol drug
delivery to their children. As a result, parents report
poor response to inhalation therapy to their physicians
who usually decide to increase the dose or change the
inhaled agent as they assume parents’ technique in
[18]
aerosol drug delivery is adequate . Therefore, parental
awareness and training on proper technique with each
interface during inhalation therapy is essential. Table 1
includes descriptions, advantages and disadvantages
of each interface used for aerosol drug delivery to
spontaneously breathing neonates and pediatrics.
After careful instructions on how to use and handle an
aerosol device, clinicians should reinforce instructions on
a regular basis and the choice of drug delivery interface
[58]
should be re-assessed .
In conclusion, delivering aerosolized drugs through
different interfaces to children poses a number of
challenges. Clearly, there is a need to develop more acce
ptable and child-friendly interfaces in order to improve
aerosol drug delivery to this patient population. New
interfaces should take into account the special needs
and respiratory characteristics of children. Meanwhile,
educating parents and healthcare professionals about
drug delivery interfaces used in inhalation therapy is

VALVED-HOLDING CHAMBERS
VHCs are commonly used with pMDIs in order to decrea
se oropharyngeal deposition and minimize hand-breath
[12,51]
coordination in children
. According to previous
research, spacers and VHCs should be washed with
detergent and air-dry to eliminate static charge and
[52-55]
improve aerosol delivery to infants and pediatrics
.
Thus, deposition of drug particles on the inner surface
of the spacer or VHC will be eliminated. Another alter
native would be to use anti-static spacers/VHCs during
[56]
inhalation therapy in children .
Also, infants and toddlers may not empty aerosolized
medication from a large volume spacer of 200-700 mL.
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essential for the well-being of neonates and pediatrics.
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